☏ +1 650 501 5505 ✉ [email protected]
Drug Pipeline Review Therapy area: Waldenstrom Macroglobulinemia40–50 pages · PDF + Excel tracker

Waldenstrom Macroglobulinemia Drug Pipeline: 29 Assets by Phase

Waldenstrom Macroglobulinemia pipeline: 29 drug candidates in clinical development, 3 in Phase III, from 25 sponsors. Data as of 4 Oct 2026.

Pipeline Terminal Waldenstrom Macroglobulinemia Data as of 4 Oct 2026
Candidates in development 29assets Desk-reviewed How this number is madeEvery drug named in an interventional trial, merged across code, generic and brand names, with a live or recent industry trial. Placebo and comparator arms excluded.
Phase III 310% of pipeline Registry How this number is madeCandidates whose highest phase in a live or recent trial is Phase III (Phase II/III counts as Phase II).
Phase II 517% of pipeline Registry
Phase I 2172% of pipeline Registry
Sponsors 25top 5 hold 31% Registry How this number is madeCompanies credited with at least one candidate: the lead sponsor on most of that candidate's industry trials.
Registered trials 17277 running Registry How this number is madeInterventional trials on ClinicalTrials.gov for the conditions in scope, updated since 4 Oct 2021.
Readouts in 12 months 3Phase II or later Sponsor dates How this number is madeCandidates with a registered primary completion date in the next 12 months. Dates are the sponsor's own and often move.
Trials with US sites 12975% · Europe 19% Registry How this number is madeTrials with at least one site in the United States; Europe is the EU/EEA, the UK and Switzerland. A trial counts in every region where it has a site.

Candidates by highest phase reached

Phase I21
Phase II5
Phase III3

Next registered primary completions, Phase II or later

CandidatePhasePrimary completion
RituximabPhase IIDec 2026 (est.)
AcalabrutinibPhase IIDec 2026 (est.)
IbrutinibPhase IIIDec 2026 (est.)

Candidates in development by lead sponsor

AbbVie2
Guangzhou Lupeng Pharmaceutical Company LTD.2
Nurix Therapeutics, Inc.2
BeOne Medicines2
Accutar Biotechnology Inc1

Phase II and III primary completions per quarter

Q4 20263
Q1 20270
Q2 20270
Q3 20270
Q4 20270
Q1 20281
Q2 20281
Q3 20280

Answers at a glance

  • 3 of 29 Waldenstrom macroglobulinemia candidates (10%) are in Phase III.
  • AbbVie runs the largest Waldenstrom macroglobulinemia pipeline, with 2 candidates.
  • 3 readouts are due in 12 months; the next is Rituximab in Dec 2026.
  • 35 trials are recruiting patients now; 75% of all trials have a US site and 19% a European one.
29 candidates172 trials38 countriesData as of 4 Oct 2026Next refresh by 2 Jan 2027
USD 3,000Pipeline Snapshot Download Free Sample Request the Review
Edition: data as of 4 Oct 2026 Next refresh: by 2 Jan 2027 Change: First edition

Request a free sample

A sample of the Waldenstrom Macroglobulinemia Pipeline Review: the full chapter list, the tracker columns and two asset profiles from the report. The Research Desk reviews your request and emails it, usually within one business day.

Waldenstrom Macroglobulinemia has 29 drug candidates in active clinical development, of which 3 are in Phase III, 5 in Phase II and 21 in Phase I, according to Douglas Insights' count of 172 interventional trials registered on ClinicalTrials.gov (data as of 4 Oct 2026).

The Waldenstrom macroglobulinemia drug pipeline is the set of medicines that sponsors are still testing in people for this condition: each candidate is counted once, at the highest phase it has reached in a running or recently completed trial. Medicines already on the market and studied only in Phase IV trials are kept out of the count.

How many Waldenstrom macroglobulinemia drugs are in each phase of development?

Douglas Insights counts 3 Waldenstrom macroglobulinemia candidates in Phase III, 10% of the 29 assets in development; Phase II holds 5 and Phase I holds 21.

Phase I21Phase II5Phase III3
Candidates by highest phase reached. Source: Douglas Insights from ClinicalTrials.gov, data as of 4 Oct 2026.
Phase (highest reached)AssetsShare of pipeline
Phase III310%
Phase II517%
Phase I2172%
Total29100%

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each Waldenstrom macroglobulinemia asset appears in exactly one row. The 77 trials still recruiting or running carry 45% of the 172 registered trials in scope.

How many Waldenstrom macroglobulinemia trials are recruiting patients now?

35 Waldenstrom macroglobulinemia trials are recruiting patients and 10 more have not started recruiting yet, out of 172 interventional trials in scope; together they make up 26% of the trial base.

Registry statusTrialsShare
Completed6940%
Recruiting3520%
Active, not recruiting3219%
Terminated1810%
Not yet recruiting105.8%
Status not verified52.9%
Withdrawn31.7%

Terminated, suspended and withdrawn Waldenstrom macroglobulinemia trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the Waldenstrom macroglobulinemia pipeline?

AbbVie leads the Waldenstrom macroglobulinemia pipeline with 2 candidates; the top 5 sponsors hold 31% of the 29 assets, and 25 sponsors run at least one.

SponsorAssets in developmentShare
AbbVie26.9%
Guangzhou Lupeng Pharmaceutical Company LTD.26.9%
Nurix Therapeutics, Inc.26.9%
BeOne Medicines26.9%
Accutar Biotechnology Inc13.4%

Industry sponsors lead 56 of the 172 Waldenstrom macroglobulinemia trials (33%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the Waldenstrom macroglobulinemia pipeline?

Mechanism and drug-type classification for the 29 Waldenstrom macroglobulinemia candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What Waldenstrom macroglobulinemia trial readouts are coming next?

3 Waldenstrom macroglobulinemia candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

CandidateSponsorPhasePrimary completionRegistry
RituximabAltor BioSciencePhase IIDec 2026 (estimated)NCT05065554
AcalabrutinibAcerta Pharma BVPhase IIDec 2026 (estimated)NCT05065554
IbrutinibJanssen Research & Development, LLCPhase IIIDec 2026 (estimated)NCT01804686

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many Waldenstrom macroglobulinemia readouts fall in each quarter?

5 Waldenstrom macroglobulinemia candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 3, due in Q4 2026.

QuarterPhase III readoutsPhase II readoutsTotal
Q4 2026123
Q1 2027000
Q2 2027000
Q3 2027000
Q4 2027000
Q1 2028011
Q2 2028011
Q3 2028000

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most Waldenstrom macroglobulinemia trials?

United States hosts the most Waldenstrom macroglobulinemia trials, with sites in 129 of the 172 studies (75%); trials in scope run in 38 countries in all.

CountryTrials with a siteShare of trials
United States12975%
China2213%
France2213%
Italy158.7%
Spain158.7%
United Kingdom158.7%
Australia148.1%
Germany127.0%

A multinational Waldenstrom macroglobulinemia trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are Waldenstrom macroglobulinemia drugs being tested?

129 of the 172 Waldenstrom macroglobulinemia trials (75%) have a site in the United States, 33 (19%) in Europe and 22 (13%) in China; 25 of the 29 candidates in development are tested in the US.

RegionTrials with a siteShare of trialsCandidates testedRegulator
United States12975%25FDA
Europe (EU/EEA, UK, Switzerland)3319%17EMA, MHRA, Swissmedic
China2213%8NMPA
Japan84.7%7PMDA
Rest of world2816%18national regulators

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational Waldenstrom macroglobulinemia trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the Waldenstrom macroglobulinemia pipeline since the last update?

This is the first edition of the Waldenstrom macroglobulinemia pipeline count, dated 4 Oct 2026. The next refresh is due by 2 Jan 2027, and each refresh lists the assets that entered, advanced or dropped out.

How does Douglas Insights count the Waldenstrom macroglobulinemia pipeline?

Douglas Insights read 172 interventional trials registered on ClinicalTrials.gov for the conditions "Waldenstrom Macroglobulinemia", "lymphoplasmacytic lymphoma" and updated since 4 Oct 2021, then grouped every drug or biologic named in them into 29 unique candidates.

  1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
  2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
  3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
  4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

What does the Waldenstrom Macroglobulinemia Pipeline Review include?

The Waldenstrom Macroglobulinemia Pipeline Review covers all 29 candidates in an Excel tracker and profiles the leading 25 in a 40–50 page report, ending with the research desk's ranked view of the candidates most likely to win.

11 chapters40–50 pages25 asset profilesExcel tracker of all 29 candidates
01Executive summary and our call2–3 pp

The pipeline on one page and the desk's verdict on where Waldenstrom macroglobulinemia treatment is heading.

  • Pipeline size and phase mix
  • The three calls that matter
  • What changed since the last edition
02Disease and unmet need3 pp

Who is treated today, what current therapy leaves unmet, and how regulators judge new medicines.

  • Patient population and diagnosis
  • Treatment guidelines and gaps
  • Regulatory endpoints
03Approved therapies3 pp

The marketed medicines every Waldenstrom macroglobulinemia candidate will be measured against.

  • Marketed medicines and their sponsors
  • Post-approval trials
  • The bar a new entrant must clear
04Pipeline at a glance4 pp

Every candidate counted by phase, drug type, sponsor and country.

  • Assets by phase and drug type
  • Sponsors by size of pipeline
  • Trial footprint: US, Europe, China, Japan
05Mechanism landscape and white space5 pp

Which mechanisms are crowded and which no sponsor has entered.

  • Mechanism classes and crowding
  • Classes with no candidate yet
  • Differentiation by route and dosing
06Key asset profiles12–15 pp

The leading 25 candidates, one profile each, every claim linked to a source document.

  • Design and endpoints of the pivotal trials
  • Data to date, with sources
  • Next readout and the risk to it
07Catalyst calendar3 pp

Readouts, filings and regulatory decisions 24 months ahead.

  • Readouts by quarter
  • Filings and regulatory decisions
  • Date confidence for each event
08Deals and partnering3 pp

Who is licensing, buying and partnering in Waldenstrom macroglobulinemia, and on what terms.

  • Licensing and M&A in the area
  • Deal terms where disclosed
  • Sponsors open to partnering
09Sponsor landscape3 pp

Large pharma against biotech, and how concentrated the pipeline is.

  • Pipeline share by sponsor
  • Sponsor-by-phase matrix
  • New entrants since the last edition
10Our call: winners, risks, opportunities3–4 pp

The candidates most likely to win, ranked, with the reasoning and evidence.

  • Ranked candidates
  • Risks that could change the order
  • Openings for new entrants and investors
11Methodology and source log2 pp

How the count is built and every document behind it.

  • How candidates are counted and merged
  • Every source document listed
  • The ten quality checks

Ways to buy the Waldenstrom Macroglobulinemia review

OptionWhat you getDeliveryPrice
Pipeline SnapshotThis therapy area as published: PDF report + Excel trackerReady nowUSD 3,000Enquire
Pipeline ReviewYour indication, geography and phase cut-off; ranked calls and an analyst call2–3 weeksFrom USD 4,000Enquire
Company AssessmentOne sponsor's full pipeline against its peers2 weeksFrom USD 5,000Enquire

Email me the sample and chapter listAsk for a quote

Frequently asked questions about the Waldenstrom macroglobulinemia pipeline

How many drugs are in the Waldenstrom macroglobulinemia pipeline?

29 drug candidates are in active clinical development for Waldenstrom macroglobulinemia, with 3 in Phase III, per Douglas Insights (data as of 4 Oct 2026).

Which company has the most Waldenstrom macroglobulinemia drugs in development?

2 candidates make AbbVie the largest Waldenstrom macroglobulinemia pipeline sponsor, out of 25 sponsors counted by Douglas Insights.

When is the next Waldenstrom macroglobulinemia trial readout?

Dec 2026 is the registered primary completion of the Phase II trial of Rituximab (NCT05065554), the next Waldenstrom macroglobulinemia catalyst in Douglas Insights' calendar.

How many Waldenstrom macroglobulinemia trials run in the United States and Europe?

129 Waldenstrom macroglobulinemia trials have a US site and 33 a European site, out of 172 registered trials counted by Douglas Insights (data as of 4 Oct 2026).

How often is the Waldenstrom macroglobulinemia pipeline count updated?

90 days is the refresh cycle; this edition uses registry data as of 4 Oct 2026 and the next is due by 2 Jan 2027.

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Cite this page Douglas Insights (2026). Waldenstrom Macroglobulinemia Drug Pipeline, data as of 4 Oct 2026. https://www.douglasinsights.com/pipeline/waldenstrom-macroglobulinemia/